The AusBiotech-led Asian Investment Series confirmed that investor interest in the Australian life science industry is strong and intensifying.
Almost 400 delegates gathered to hear 21 Australian biotechnology and medical technology companies present their investment proposition as part of the Series, which was held in Singapore, Hong Kong and Shanghai during March.
AusBiotech CEO, Glenn Cross, who led the three events, said: "This strong investor interest in the Australian life sciences stems from the nation's top ranking in the global life sciences and its diverse suite of investment opportunities in biotechnology and pharmaceuticals."
Read the article, Asian Investor series confirms strong investor interest.
The events featured: